Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 15.5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The urothelial cancer drugs market studied was projected to witness a CAGR of 15.5% over the forecast period.
The emergence of COVID-19 has had a profound impact on the urothelial cancer drugs market as well. As per the data provided by the National Health Services, England on 'NHS Diagnostic Waiting Times and Activity Data', 2020, stated that the healthcare services had been devastated, globally. As of August 2020, approximately 50.2% of patients in England for cystoscopy had to wait for at least six weeks compared to 9% in 2019. Thus, this delay in diagnosis impacted negatively on the therapeutic interventions as well, thereby, limiting the market studied.
Some of the major factors bolstering the market growth are the emergence and popularity of targeted therapy and the rise in the incidence of urothelial cancer. Bladder cancer is the 10th most common malignancy, globally, according to the GLOBOCAN 2020, and the most frequently occurred type of bladder cancer is urothelial carcinoma.
As per the study titled, 'Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths,' published in December 2019, about 79.3% of the bladder cancer patients were of transitional cell carcinoma. An additional 6% showed associated squamous features.
Additionally, the urothelial cancer drugs market is likely to be benefitted from better therapies being approved by prominent drug regulatory organizations. In April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene to treat advanced/metastatic urothelial carcinoma. Several novel treatments are predicted to see approvals, further supporting the growth of the market.
Scope of the Report
Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder, which also spreads to other parts of the body. The urothelium comprises the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. Urothelial carcinoma is the most widespread bladder cancer, as it accounts for over 90% of all bladder cancers. The urothelial cancer drugs market has been segmented by treatment (chemotherapy and immunotherapy) and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Treatment | |
| Chemotherapy | |
| Immunotherapy |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Chemotherapy Under the Treatment Type is Expected to Witness the Fastest Growth Over the Forecast Period
The chemotherapy segment is expected to dominate the market by treatment type, as the drugs may be used alone or in combination, depending on the purpose of their usage. The delay in diagnosis and treatment during the pandemic situation was expected to have adversely affected the demand for chemotherapy drugs in 2020.
However, according to the Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, treatment regimens for cancer management had been modified to minimize the number of visits. They also found that patients receiving chemotherapy treatment were not at high risk of developing COVID-19. Such studies are expected to positively impact the market studied in this segment.
Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of urothelial cancer cells. It works throughout the whole body to destroy and damage cancer cells spread to other parts of the body away from the original tumor.
The chemotherapy product launches and approvals for urothelial cancer are expected to boost the market growth. For instance, in December 2019, the United States Food and Drug Administration approved Padcev (enfortumab vedotin-ejfv) developed by Astellas Pharma US Inc. and Seattle Genetics Inc. It has been indicated against the treatment of advanced urothelial cancer.
Furthermore, as per the results of 'Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomized controlled trial', published in March 2020, gemcitabine-platinum combination chemotherapy significantly improved the outcomes in patients suffering from upper tract urothelial carcinoma. Such studies are expected to aid the market growth in this segment.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period
The North American region has been dominating the urothelial cancer drugs market. With the emergence of COVID-19, a significant impact on the urothelial cancer drugs market was also observed. As a result, organizations, such as the American College of Surgeons (ACS), have released recommendations in order to guide appropriately on the treatment delays.
Due to factors, like the presence of a large target population, increased adoption of novel therapeutics, and multiple product launches, along with a rising need to tackle bladder cancer. As per the data of GLOBOCAN, in 2020, about 90,000 new cases of bladder cancer were reported in North America, and in 2040, this number is expected to reach 137,000 in North America. Most of the bladder cancer cases are urothelial cancer types. Thus, with the rising burden of bladder cancer, the burden of urothelial cancer is also expected to increase. With a large number of bladder cancer cases, increased awareness in the society and healthcare facilities with good distribution channels are some of the important factors that are expected to increase the market growth over the forecast period.
To understand geography trends, Download Sample Report
Competitive Landscape
The urothelial cancer drug market is consolidated. However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. Few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the urothelial cancer drugs market crowded with new products in the next couple of years. Some of the major players in the urothelial cancer drugs market are Merck & Co. Inc., F Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, and Novartis AG, among others.
Recent Developments
- In June 2020, Pfizer received the United States Food and Drug Administration approval for BAVENCIO. It has been approved as a first-line maintenance treatment among patients suffering from advanced/metastatic urothelial carcinoma.
- In April 2020, UroGen Pharma received the United States Food and Drug Administration approval for mitomycin gel (Jelmyto), which has been indicated for the treatment of low-grade upper tract urothelial cancer.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence and Priority of Targeted Therapy Among Biopharmaceutical Companies
4.2.2 Growing Burden of Urothelial Cancer
4.3 Market Restraints
4.3.1 Side Effects Associated with Drugs
4.3.2 Regulatory Issues
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Chemotherapy
5.1.2 Immunotherapy
5.2 By Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 F Hoffmann-La Roche AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 AstraZeneca PLC
6.1.5 Novartis AG
6.1.6 GlaxoSmithKline PLC
6.1.7 Sanofi SA
6.1.8 Eisai Co. Ltd
6.1.9 Astellas Pharma
6.1.10 UroGen Pharma
6.1.11 Pfizer Inc.
6.1.12 Genentech USA Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Urothelial Cancer Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Global Urothelial Cancer Drugs Market?
The Global Urothelial Cancer Drugs Market is growing at a CAGR of 15.5% over the next 5 years.
Which region has highest growth rate in Global Urothelial Cancer Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Urothelial Cancer Drugs Market?
North America holds highest share in 2020.
Who are the key players in Global Urothelial Cancer Drugs Market?
Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, F Hoffmann-La Roche AG are the major companies operating in Global Urothelial Cancer Drugs Market.
